TSHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TSHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Taysha Gene Therapies has the Growth Rank of 0.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
Thank you for viewing the detailed overview of Taysha Gene Therapies's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Alison S Long | director | KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Kamran Alam | officer: Chief Financial Officer | 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118 |
Sean P. Nolan | director | C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005 |
Phillip B. Donenberg | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Session R.a. Ii | 10 percent owner | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015 |
Sukumar Nagendran | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Astellas Pharma Inc. | 10 percent owner | 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411 |
Audentes Therapeutics, Inc. | 10 percent owner | 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108 |
Suyash Prasad | officer: CMO and Head of R&D | C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104 |
Laura Sepp-lorenzino | director | C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139 |
Kathleen Reape | director | C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235 |
From GuruFocus
By GuruFocus Research • 08-13-2024
By Marketwired • 10-22-2024
By Marketwired • 08-05-2024
By GuruFocus News • 11-15-2024
By Marketwired • 06-12-2024
By Marketwired • 11-06-2024
By Marketwired • 06-18-2024
By GuruFocus News • 02-12-2025
By GuruFocus News • 11-14-2024
By Marketwired • 09-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.